[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Parkinson's Disease: Molecular Landscape & Future Disease Modifying Targeted Therapies

September 2018 | 34 pages | ID: P2FED31302CEN
ProGrow Pharma Partners

US$ 3,200.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Continuing our efforts to focus on novel targeted therapies in the making we are publishing our latest in the series“ Parkinson's Disease -Molecular Landscape & Future Disease Modifying Targeted Therapies”

The success of targeted therapies in indications like cancer, chronic diseases (diabetes, RA, Psoriasis etc.) have paved the way for using this approach in more challenging indications like Parkinson’s, Migraine, Alzheimer’s and other neurological diseases. The key driver behind these efforts is the unravelling of the complex biology and pathogenesis of the disease and availability of novel technology, formulation platforms to aid in the translation of “bench side results” into a commercial product.

This report is aimed for Strategic decision makers in the pharma companies, financial world to gain new insights into the science of the disease, challenges as well as the commercial opportunity awaiting should a few of the drugs in pipeline make it to the market There are several reports on PD but few which are comprehensive both in defining the molecular landscape in PD, unmet need, promising drugs in the pipeline their commercial aspect . This report is a must for those who like to have an “in depth analysis” of drugs promising to shape the future.
1. EXECUTIVE SUMMARY

2. DISEASE OVERVIEW

Pathogenesis and Types
Prevalence
Current Treatment Paradigm
Approved Drugs
Unmet Needs

3. MOLECULAR LANDSCAPE: NEW INSIGHTS AND GENETIC PROFILING

Key Genes being Targeted by New Drugs in Development
  1. SNCA (PARK1–4)
  2. The GBA1 Gene and the GCase Protein
  3. Parkin (PARK2)
  4. PINK1 (PARK6)
  5. DJ-1 (PARK7)
  6. LRRK2: Leucine-Rich Repeat Kinase-2 Gene (PARK8)
  7. ATP13A2 (PARK9)

4. THERAPEUTICS IN DEVELOPMENT

Targeting Specific Genes/proteins
  LRRK2
  Targeting alpha-synuclein (aSyn)
Improved Formulation of Approved Drugs for PD
Repurposed Drugs
Others

5. MARKET OPPORTUNITY


More Publications